A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults withRelapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), COG ID AALL1621/Pfizer No. WI221468

Project: Research project

Project Details

Description

A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), COG ID AALL1621/Pfizer No. WI221468
StatusActive
Effective start/end date4/1/223/31/23

Funding

  • Public Health Institute

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.